156
Participants
Start Date
December 31, 2013
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
Vildagliptin (LAF237)
Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
Placebo
Matching placebo of vildagliptin 50 mg twice daily
Insulin
"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
Metformin
Patients continued their prescribed metformin dose, if applicable.
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukutsu
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kōriyama
Novartis Investigative Site, Mito
Novartis Investigative Site, Ibusuki
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Yatsushiro
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Sendai
Novartis Investigative Site, Hirakata
Novartis Investigative Site, Izumisano
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Takatsuki
Novartis Investigative Site, Ageo
Novartis Investigative Site, Saitama
Novartis Investigative Site, Sayama
Novartis Investigative Site, Tokorozawa
Novartis Investigative Site, Adachi-ku
Novartis Investigative Site, Chiyoda-ku
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Chuo-ku
Novartis Investigative Site, Nerima-ku
Novartis Investigative Site, Nerima-ku
Novartis Investigative Site, Ōta-ku
Novartis Investigative Site, Suginami-ku
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY